Interstitial Lung Disease Clinical Trials

Find Interstitial Lung Disease Clinical Trials Near You

Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study focuses on both hospitalized and outpatient populations. Through a multicenter, retrospective study, it aims to comprehensively characterize:The comorbidity of interstitial lung diseases (ILD) and airway diseases;The comorbidity of ILD with other intrapulmonary diseases;The comorbidity of airway diseases with other intrapulmonary diseases;The comorbidity of ILD and airway diseases with extrapulmonary diseases.Based on these findings, the study seeks to propose classification and diagnostic criteria for ILD and airway disease comorbidities.Additionally, a multicenter, prospective, disease-specific cohort study will be conducted to observe the prognosis of patients with ILD and/or airway diseases, identify prognostic factors, and grade the severity of comorbid conditions based on these factors.Finally, the study will analyze the current state of interventions and the medical costs associated with ILD and airway disease comorbidities through a cost-effectiveness analysis, aiming to propose new strategies for integrated disease management.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:

• age between 40-80 years old;

• inpatients with an admission diagnosis of COPD, Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, patients with the following diagnoses were screened by chest CT (slice thickness ≤1.5 mm) during hospitalization and by in-hospital or prior pulmonary function;

• Inpatients who meet the criteria can complete pulmonary function tests and chest HRCT examinations within one month before expected discharge (excluding hospitalized patients with stable interstitial lung disease or airway disorders);

• among outpatients, patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, COPD with pulmonary interstitial abnormalities, idiopathic pulmonary fibrosis with airway lesions, nonspecific interstitial pneumonia with airway lesions, pulmonary fibrosis with emphysema syndrome were diagnosed through chest CT (layer thickness ≤1.5mm) and lung function;

• provide informed consent.

Locations
Other Locations
China
Xiangya Hospital
RECRUITING
Changsha
Contact Information
Primary
Ruoxi He, MD
heruoxi@csu.edu.cn
86+18874167666
Backup
Wei Cheng, MD
urnotchengwei@csu.edu.cn
86+18274860269
Time Frame
Start Date: 2025-05-20
Estimated Completion Date: 2028-11-30
Participants
Target number of participants: 900
Treatments
COPD with ILA
Chronic obstructive pulmonary disease complicated with interstitial lung abnormalities: patients were treated routinely without additional intervention.
PF with emphysema syndrome
Pulmonary fibrosis with emphysema syndrome: patients were treated routinely without additional intervention.
NSIP
Nonspecific interstitial pneumonia: patients were treated routinely without additional intervention.
IPF
Idiopathic pulmonary fibrosis: patients were treated routinely without additional intervention.
COPD
Chronic obstructive pulmonary disease: patients were treated routinely without additional intervention.
NSIP with airway disease
Nonspecific interstitial pneumonia with airway disease: patients were treated routinely without additional intervention.
IPF with airway disease
Idiopathic pulmonary fibrosis with airway disease: patients were treated routinely without additional intervention.
Sponsors
Collaborators: China-Japan Friendship Hospital, Henan Provincial People's Hospital, Zhejiang University, Zhongshan Hospital (Xiamen), Fudan University, Beijing Hospital, The Affiliated Hospital of Qingdao University, First Hospital of China Medical University, The Affiliated Hospital Of Guizhou Medical University
Leads: Xiangya Hospital of Central South University

This content was sourced from clinicaltrials.gov